CANCER PANELS

 

Cancer panels use next generation sequencing (NGS) technology to target specific genes or mutations that have established relevancy to a particular cancer phenotype. NGS facilitates sequencing of large genomic regions, high numbers of genes, and/or high numbers of samples in a single, efficient and cost-effective assay. In addition, NGS provides significantly higher sensitivity than traditional techniques, which permits the discovery of rare somatic mutations, many of which have been identified as important cancer drivers.

Azenta offers several cancer panels to provide a complete solution from experimental design to advanced bioinformatics analysis. Each panel can be combined with any of our genomics, transcriptomics, proteomics, and epigenomics services for a multiomics approach, providing crucial insights into human cancer profiles and defining patterns that would have remained unseen and incomplete with just a single assay.

 

SERVICE OPTIONS

  • Azenta’s most comprehensive cancer panel, our pan-cancer panel offers coverage of all exons for 634 known tumor suppressors and oncogenes. The panel can be easily multiplexed to accommodate studies of virtually any size and is ideal for biomarker discovery and validation, as well as patient stratification.

  • Azenta OncoGxOne™ Discovery cancer panels provide comprehensive genomic analysis for cancer research, biomarker discovery, and patient stratification for clinical discovery. These assays provide thorough assessments of 150 - 400 cancer genes of interest utilizing 19 distinct gene panels, each of which assays a specific cancer (organ) type.

  • Hotspot cancer panels assay multiple cancer types with a single gene panel to target well-characterized, small regions of known cancer genes (~48 genes). The small target region size produces a high depth of sequencing coverage per sample, even when multiplexing, to provide a cost-effective and efficient method for discovering rare somatic mutations.

Features & Benefits


Extremely high depth of coverage to detect common and rare mutations

Very low input DNA requirement

Sequencing compatibility with FFPE samples

Capability to detect somatic point mutations, INDELs, gene fusions, and copy number variations (CNV)

Customizability of select cancer panels to add additional genes of interest

Dedicated support from experienced Ph.D. scientists

Complete solution, from project design through custom data analysis

Fast turnaround time with expedited options available

Cancer Panel Comparison


Azenta Pan-Cancer Pane GENEWIZ OncoGxOneTM
Discovery Cancer Panels
Illumina TruSeq©
Amplicon Cancer Panel
Sequencing Platform Illumina MiSeq or HiSeq Illumina MiSeq or HiSeq Illumina MiSeq
Cancer Types Assayed Single gene panel assay for multiple cancer types
19 distinct gene panels, each assays a specific cancer (organ) type Single gene panel assays multiple cancer types
Genes Covered 634 ≈150 - 400 48
Genomic Variation Detection
  • Point Mutations
  • Indels
  • Copy Number Variations (CNV)
  • Point Mutations
  • Indels
  • Rearrangements
  • Copy Number Variations (CNV)
  • Point Mutations
  • Indels
Target Regions ≈ 2 Mb, consisting of exons and targeted promoter regions ≈ 2 - 5.4 Mb, consisting of all exons, UTRs, and relevant intron regions ≈35 Kb, consisting of mutational hot spots
Average Depth >100x* > 100x* > 100x*
Target Enrichment Twist Targeted Enrichment Agilent SureSelect Targeted Enrichment Illumina Targeted Amplicon Sequencing
DNA Input > 100 ng > 100 ng > 250 ng
Sample Submission
  • FFPE thin sections (slides)
  • gDNA
  • Fresh, frozen samples
  • FFPE thin sections (slides)
  • gDNA
  • Fresh, frozen samples
  • FFPE thin sections (slides)
  • gDNA
*Additional depth of coverage is available by request.

Sample Submission Guidelines

GENEWIZ accepts formalin-fixed, paraffin-embedded (FFPE) thin sections (slides), purified genomic DNA, or fresh, frozen samples for Cancer Panel projects. For detailed sample submission requirements please visit our Sample Submission Guidelines page.

Deliverables

All customers receive their raw data as FASTQ files. Mutation discovery repeats and customizable data analysis packages are available on request.

Technical Resources

Webinar| Non-Classical Sources of Tumour-Specific Antigen in Checkpoint Inhibitor Response

Developing immunotherapies for cancer can be difficult due to the variation of immune response from patient to patient. In this webinar, Dr. Litchfield from UCL Cancer Institute presents his team’s exploratory research using a multiomics approach to better understand the diversity of immune response to cancer and highlights their findings of an alternative source of a tumour-specific antigen in checkpoint inhibitor (CPI) response.

NGS Platforms - Now with ILLUMINA Novaseq

Azenta is a certified service provider for Illumina NGS platforms and the PacBio Sequel. Please visit our NGS Platforms page for more information.



How To Order


Email | Phone 1-877-436-3949, Ext. 1